Compare iShares MSCI South Korea ETF (EWY) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? iShares MSCI South Korea ETF trades at $148.68 (market cap $24.38B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: iShares MSCI South Korea ETF is far larger — about 2.4× Globus Medical Inc. Class A Common Stock's market cap, and iShares MSCI South Korea ETF is more actively traded (22,329,675 versus 1,108,124). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 48 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EWY | GMED | |
|---|---|---|
Market Cap | $24.38B | $10.25B |
Volume | 22,329,675 | 1,108,124 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $96.82 |
52-Week Low | $85.17 | $58.33 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.56, down 2.16% amid bearish technical signals. The ETF faces pressure from rising US yields and oil prices impacting South Korean tech stocks, though corporate earnings remain resilient with strong AI memory demand driving performance. Technical indicators show oversold conditions with RSI at 21.77 suggesting potential bounce.
Outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to semiconductor cycle volatility. While AI infrastructure spending provides growth catalyst, macroeconomic headwinds and profit-taking near 7,000 KOSPI level present near-term risks for investors.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
